KTTA Latest Press Releases

-- October 23, 2026 --

Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 Globe Newswire 9:15 AM

-- September 14, 2026 --

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference Globe Newswire 7:00 AM

-- September 3, 2026 --

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences Globe Newswire 4:05 PM

-- July 21, 2026 --

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026 Globe Newswire 7:00 AM

-- July 8, 2026 --

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit Globe Newswire 7:02 AM

-- June 30, 2026 --

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion Globe Newswire 7:00 AM

-- June 16, 2026 --

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial Globe Newswire 7:00 AM

-- June 15, 2026 --

Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference Globe Newswire 7:02 AM

-- June 2, 2026 --

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Globe Newswire 7:02 AM

Market Data Delayed 15 Minutes